Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

<< Previous

Bullboard Posts

Next >>

Post by scarlet1967on Mar 17, 2021 10:19am

104 Views

Post# 32815745

Glycemic Control Predicts Severity of Hepatic Fibrosis

To understand the etiology of NAFLD/NASH is the key to find a cure for the conditions, same applies to other diseases.

As per the article posted on PubMed.gov on Mach 16, 2021 the average blood sugar levels is a reliable predictor of liver fibrosis, Tesamorelin deceases insulin resistance therefor more regulated blood sugar.

“Glycemic control predicts severity of ballooned hepatocytes and hepatic fibrosis in NAFLD/NASH, and thus optimizing glycemic control may be a means of modifying risk of NASH-related fibrosis progression.”

https://pubmed.ncbi.nlm.nih.gov/33724511/

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market